Sponsor

ModernaTX, Inc.

Clinical research sponsor

Published trials16
Recruiting shown4
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

16 shown
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsNCT06735248 · lead sponsor · 2025-04-16
RECRUITING
A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart FailureNCT05659264 · lead sponsor · 2022-12-05
COMPLETED
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced MalignanciesNCT03739931 · lead sponsor · 2018-11-27
COMPLETED
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)NCT07513376 · collaborator · 2026-05-04
RECRUITING
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)NCT07221474 · collaborator · 2025-12-12
RECRUITING
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · collaborator · 2024-10-21
RECRUITING
Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.NCT06694753 · collaborator · 2025-12-15
ACTIVE_NOT_RECRUITING
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).NCT06307431 · collaborator · 2024-04-10
ACTIVE_NOT_RECRUITING
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)NCT06305767 · collaborator · 2024-03-28
ACTIVE_NOT_RECRUITING
COVID19 OutcomeS in Myeloma and the Impact of VaCcinesNCT05831787 · collaborator · 2024-01-23
COMPLETED
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 · collaborator · 2023-12-06
ACTIVE_NOT_RECRUITING
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)NCT05001373 · collaborator · 2021-11-12
UNKNOWN
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer PatientsNCT05054218 · collaborator · 2021-09-10
COMPLETED
Immunocompromised Swiss Cohorts Based Trial PlatformNCT04805125 · collaborator · 2021-04-19
COMPLETED
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)NCT03948763 · collaborator · 2019-06-26
TERMINATED
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)NCT02872025 · collaborator · 2016-12-12
ACTIVE_NOT_RECRUITING

Sponsor roles

collaborator13
lead sponsor3
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.